恩瑞格治疗铁质积聚的效果如何呢？

It should be taken on an empty stomach at least 30 minutes before a meal, once a day, preferably at the same time every day. Tablets should not be chewed or swallowed whole. Enriga should not be taken with aluminum-containing antacids, and the dosage (mg/kg) needs to be calculated and rounded to the nearest whole tablet.

So how effective is Enrig in treating iron buildup?

Therapeutic effects of Enrige in treating iron accumulation:

To analyze the clinical efficacy and adverse reactions of the new iron chelator Enriga in the treatment of secondary iron overload in myelodysplastic syndrome (MDS).

This retrospective analysis was conducted on the clinical data of patients with secondary iron overload in MDS who were treated with the new iron chelator Enriga at the People's Liberation Army General Hospital from January 2012 to April 2014. The serum ferritin (SF), red blood cell transfusion volume, hemoglobin and adverse drug reactions before and after treatment were observed.

Results: A total of 8 MDS patients with secondary iron overload took Enriga, including 7 males and 1 female, with a median age of 52 (38-71) years old. After 3 months of treatment, the efficacy was evaluated as complete response (CR) in 3 cases, minimal reaction (MiR) in 3 cases, and stable iron overload (SIL) in 2 cases. The overall response rate was 75.0% (6/8), and the median red blood cell transfusion volume was 2 (1-3) u/month. After 1 year of treatment, the efficacy was evaluated as CR in 5 cases, MiR in 2 cases, and SIL in 1 case. The overall response rate was 87.5% (7/8).

Compared with before treatment, the patient's SF was significantly reduced [(871.0±584.2) vs (2164.9±1233.6) ng/ml] and hemoglobin was significantly increased [(101.5±34.59) vs (65.37±21.35) g/L] after 1 year of treatment, and the differences were statistically significant (P<0.05). After 1 year, 5 patients were weaned from blood transfusion, and the median red blood cell transfusion volumes of the remaining 3 patients were 0.5 u/month, 1.5 u/month, and 2.0 u/month respectively. After 1 year of treatment, only one patient died. There were 3 cases of nausea and vomiting and 1 case of diarrhea after taking the medicine.

Conclusion: It is safe and effective to treat secondary iron overload in MDS.